Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT02546531, this PHASE1 trial focuses on Advanced Solid Tumors and Pancreatic Cancer and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 17 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Jun 2022 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 12 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Dec 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2019 — Dec 2019 [monthly]
Recruiting PHASE1
-
Dec 2018 — Mar 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Feb 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Mar 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- The Foundation for Barnes-Jewish Hospital
- Verastem, Inc.
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Rochester, United States
- • St Louis, United States